Eventide Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Eventide Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,394,336	Closed	-$2.37M	–	256
2025 Q1	$2.37M	Hold	1,394,336	–	–	0.05%	159
2024 Q4	$4.45M	Hold	1,394,336	–	–	0.08%	156
2024 Q3	$3.13M	Hold	1,394,336	–	–	0.05%	148
2024 Q2	$3.13M	Hold	1,394,336	–	–	0.05%	141
2024 Q1	$3.13M	Hold	1,394,336	–	–	0.05%	141
2023 Q4	$3.25M	Buy	+1,394,336	New	+$4.35M	0.05%	137
2018 Q2	–	Sell	-347	Closed	-$940K	–	151
2018 Q1	$940K	Buy	+347	New	+$844K	0.04%	134

Other funds holding VYNE

Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $699M AUM 600.17% 1-Year Est. Return